Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 259

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 259
---
 comprehensive loss. Components of lease cost for the years ended December 31, 2024 and 2023, respectively, were as follows (in thousands):

        Year EndedDecember 31,

        2024

        2023

        Operating lease cost
         
        $
        957

        $
        708

        Short-term lease cost

        90

        61

        Variable lease cost

        127

        79

        Total lease cost
         
        $
        1,174

        $
        848

      Maturities of lease liabilities, weighted-average remaining term and weighted-average discount rate were as follows (in thousands):

        As of December 31,

        Year ending December 31,

        2025
         
        $
        874

        2026

        900

        2027

        927

        2028

        955

        2029

        983

        Thereafter

        4,048

        Total minimum lease payments

        8,687

        Less: amount representing interest

        (2,465
        )

        Present value of lease liabilities

        6,222

        Less: current portion of lease liabilities

        (412
        )

        Lease liabilities, noncurrent
         
        $
        5,810

135

        December 31,

        December 31,

        2024

        2023

        Weighted-average remaining lease term (years) - operating leases

        8.9

        9.9

        Weighted-average incremental borrowing rate - operating leases

        8.07
        %

        8.07
        %

11. Commitments and ContingenciesOther Funding CommitmentsAs of December 31, 2024, the Company had ongoing clinical and pre-clinical studies for its various programs. The Company enters into contracts in the normal course of business with contract research organizations in preparation for clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts are generally cancellable, with notice, at the Company's option and do not have significant cancellation penalties.Litigation The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of December 31, 2024, and no material legal proceedings are currently pending or threatened.